MetaCap

Medicinova Inc (MNOV)

NASDAQ: MNOVHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.31+0.04 (+3.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MNOV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$67.11M
EPS (TTM)
-$0.21
52-week range
1.22 – 3.90
Day range
1.27 – 1.31
Volume / Avg
48.97K / 334.96K
Beta
—

52-week range

$1.22$3.90

MNOV stock today

Medicinova (MNOV) closed at $1.31 on Nov 20, up 3.15% (+$0.04), versus the S&P 500's 3.70% decline. Trading was light, with 48.97K shares changing hands, about 15% of the average daily volume. At this level, MNOV sits near the bottom of its 52-week range of $1.22 to $3.90: 66.4% below the high, set on Sep 17, 2026 and 7.4% above the low.

MNOV is up 0.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.4%. Medicinova has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Medicinova

Company profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Yuichi Iwaki M.D., Ph.D.
Headquarters
La Jolla, CA
Employees
6

Financial highlights

Full financials

In fiscal 2025, Medicinova generated $409,657 in revenue. Medicinova reported a net loss of $12.0 million, compared with a loss of $11.0 million a year earlier. Operating margin was -3242.5%.

Medicinova annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$409.66K—$1.00M—$4.04M
Growth—————
Net income$-12.00M$-11.05M$-8.57M$-14.07M$-10.13M
EPS (diluted)$-0.24$-0.23$-0.17$-0.29$-0.21

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$8.25+529.77%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.06 vs $-0.06

MNOV news

All MNOV news

Medicinova peers

Health Care sector
MNOV peer companies
CompanyPrice% ChgMarket capCompare
CINGCingulate Inc.4.51-14.26%$67.48Mvs MNOV
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs MNOV
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs MNOV
MAIAMAIA Biotechnology Inc.1.11-2.63%$68.54Mvs MNOV
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs MNOV
COYACoya Therapeutics Inc.2.95-1.01%$69.20Mvs MNOV
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs MNOV
ZYBTZhengye Biotechnology Holding Limited Class A1.48-2.63%$70.14Mvs MNOV

Indexes, lists and sector

Medicinova stock FAQ

What is Medicinova's stock price today?

MNOV last traded at $1.31 as of Nov 20, 4:00 PM EST, up 3.15% on the day. Prices are delayed at least 15 minutes.

Who is Medicinova's CEO?

Dr. Yuichi Iwaki M.D., Ph.D. is the chief executive officer of Medicinova Inc, which has about 6 employees.

What is the MNOV 52-week high?

The 52-week high for MNOV is $3.90 and the 52-week low is $1.22. The stock is currently 66.4% below its high.

Compare MNOV